Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Two-Part (Dose Escalation and Expansion) Study of DEM301 in Participants With Select Advanced Solid Tumors

NCT07805369 is registered in ClinicalTrials.gov with DEM BioPharma, Inc. as lead sponsor.

NCT NCT07805369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07805369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Two-Part (Dose Escalation and Expansion) Study of DEM301 in Participants With Select Advanced Solid Tumors
Lead sponsor
DEM BioPharma, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
March 31, 2029
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer, metastatic colorectal cancer, rectal cancer